StockNews.com Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday.

Other research analysts have also issued reports about the company. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. TD Cowen increased their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Finally, Leerink Partners restated a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $1,118.62.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $1,039.96 on Wednesday. The firm has a 50-day moving average of $1,129.87 and a two-hundred day moving average of $1,033.99. The firm has a market capitalization of $114.59 billion, a PE ratio of 30.60, a P/E/G ratio of 3.72 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter last year, the business posted $8.79 EPS. The company’s revenue was up 12.3% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,270 shares of company stock worth $10,695,833. 7.48% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Greater Midwest Financial Group LLC increased its holdings in Regeneron Pharmaceuticals by 8.8% in the 2nd quarter. Greater Midwest Financial Group LLC now owns 2,502 shares of the biopharmaceutical company’s stock valued at $2,894,000 after buying an additional 203 shares during the period. Centaurus Financial Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $118,000. Prio Wealth Limited Partnership acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $210,000. Sanctuary Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at about $47,611,000. Finally, Kestra Investment Management LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter worth about $437,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.